Mainz Biomed Announces Stock Split
Ticker: MYNZ · Form: 6-K · Filed: Nov 29, 2024 · CIK: 1874252
| Field | Detail |
|---|---|
| Company | Mainz Biomed N.V. (MYNZ) |
| Form Type | 6-K |
| Filed Date | Nov 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: stock-split, filing, corporate-action
TL;DR
Mainz Biomed doing a stock split, filing shows.
AI Summary
Mainz Biomed N.V. announced a stock split on November 29, 2024. This filing incorporates by reference a press release detailing the stock split, which is furnished as Exhibit 99.1. The company is a foreign private issuer filing a Form 6-K for the month of November 2024.
Why It Matters
A stock split can make shares more accessible to a wider range of investors by lowering the per-share price, potentially increasing liquidity.
Risk Assessment
Risk Level: low — The filing is an informational report about a stock split, not a financial distress or major operational change.
Key Players & Entities
- Mainz Biomed N.V. (company) — Registrant
- November 29, 2024 (date) — Date of press release and filing
- Exhibit 99.1 (document) — Incorporated press release
- Form 6-K (document) — Filing type
- Form F-3 (File No. 333-269091) (document) — Registration statement where information is incorporated
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to furnish a press release dated November 29, 2024, announcing a stock split, as Exhibit 99.1.
When was the press release announcing the stock split dated?
The press release announcing the stock split was dated November 29, 2024.
What is the company's filing status regarding annual reports?
The company indicates it files annual reports under cover of Form 20-F.
Where is Mainz Biomed N.V. located?
Mainz Biomed N.V.'s principal executive office is located at Robert Koch Strasse 50, 55129 Mainz, Germany.
Into which registration statement is the information in this Form 6-K incorporated?
The information is incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-269091).
Filing Stats: 202 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2024-11-29 08:45:23
Filing Documents
- ea0223050-6k_mainzbio.htm (6-K) — 10KB
- ea022305001ex99-1_mainzbio.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-24-103761.txt ( ) — 48KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant’s name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Other Events Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release dated November 29, 2024 entitled “Mainz Biomed Announces Stock Split.” The information contained in this Report on Form 6-K is hereby incorporated by reference into our Registration Statement on Form F-3 (File No. 333-269091 ). Exhibit No. Exhibit 99.1 Press Release entitled “Mainz Biomed Announces Stock Split” 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 29, 2024 By: /s/ William J. Caragol Name: William J. Caragol Title: Chief Financial Officer 2